Primary Sclerosing Cholangitis with Markedly Elevated Serum IgG4 (>140 mg/dl)
A subset of patients with primary sclerosing cholangitis (PSC) present with markedly elevated serum IgG4 levels exceeding 140 mg/dl. While mild IgG4 elevations are relatively common in PSC, this marked elevation is clinically significant and directly shapes the management strategy.
Clinical scenario: PSC in a patient with markedly elevated serum IgG4 (>140 mg/dl). This laboratory finding distinguishes the case from typical PSC and calls for a management approach that differs from standard PSC care.
Treatment approach
Management in this scenario centres on immunosuppressive therapy. The specific agents and the full structured approach — including sequencing and monitoring considerations — are available in the complete protocol.
References
DOI: 10.1038/ajg.2015.112
- A subset of patients with PSC have marked elevations of IgG4 levels (>140 mg/dl), although mild increases in IgG4 levels appear common in PSC.
- Corticosteroids or other immunosuppressive agents are generally used in patients with IgG4 cholangitis, whereas they do not have a role in PSC.
View source ↗